AI Program May Aid in Pathologic Evaluation of Breast Biopsies
FRIDAY, Aug. 16, 2019 -- An artificial intelligence program outperforms pathologists for differentiating ductal carcinoma in situ (DCIS) from atypia, according to a study published online Aug. 9 in JAMA Network Open.
Ezgi Mercan, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2019 Category: Pharmaceuticals Source Type: news
Artificial intelligence could yield more accurate breast cancer diagnoses
UCLA researchers have developed an artificial intelligence system that could help pathologists read biopsies more accurately and to better detect and diagnose breast cancer.The new system,described in a study published today in JAMA Network Open, helps interpret medical images used to diagnose breast cancer that can be difficult for the human eye to classify, and it does so nearly as accurately or better as experienced pathologists.“It is critical to get a correct diagnosis from the beginning so that we can guide patients to the most effective treatments,” said Dr. Joann Elmore, the study’s senior author and a profes...
Source: UCLA Newsroom: Health Sciences - August 9, 2019 Category: Universities & Medical Training Source Type: news
Contrast ultrasound can tell DCIS from fibroadenomas
Contrast-enhanced ultrasound can distinguish ductal carcinoma in situ (DCIS)...Read more on AuntMinnie.comRelated Reading:
Ultrasound options abound for diagnosing liver disease
ICUS applauds payment changes for CEUS
Contrast ultrasound helps characterize breast lesions
Drop ultrasound contrast agent warning, society says
Contrast US tops CT, MRI for classifying kidney tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 19, 2019 Category: Radiology Source Type: news
Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer
Cancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2019 Category: Cancer & Oncology Authors: Marleen Meyers, MD Source Type: news
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: A large study from a single institution
(Cancer Research UK) Upcoming publication from the British Journal of Cancer, investigating HER2 expression as a predictor of recurrence and development in patients with DCIS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2019 Category: Cancer & Oncology Source Type: news
Six Factors Tied to DCIS Returning as Breast Cancer Six Factors Tied to DCIS Returning as Breast Cancer
A group of six factors are associated with ductal carcinoma in situ returning as invasive breast cancer after treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Six Prognostic Factors ID'd for Invasive Disease After DCIS
THURSDAY, April 25, 2019 -- In a review published online April 25 in Cancer Epidemiology, Biomarkers& Prevention, six prognostic factors are identified that may predict invasive disease after a diagnosis of ductal carcinoma in situ... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2019 Category: Pharmaceuticals Source Type: news
Six factors may predict invasive breast cancer recurrence after DCIS diagnosis
(American Association for Cancer Research) Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to data from a meta-analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news
Smart Biopsy Device Could Diagnose Breast Cancer Using Miniature Radiofrequency Sensors
Normally, when a physician notices a suspicious mass or lesion on a mammogram, he or she will request an ultrasound to explore it further. Based on those results, a biopsy may be performed to determine whether the mass is cancerous. “Unfortunately, right now, in some cases, physicians either overdiagnose or underdiagnose based on that biopsy, because with ultrasound they can only see so much,†said Lori Chmura, CEO of Dune Medical Devices. “The doctor is essentially going in blindly, trying to see what looks like the most suspicious area, and they’re t...
Source: MDDI - March 12, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Business Source Type: news
New diagnostic technique reveals a protein biomarker that accurately differentiates bladder cancer from benign inflammation
(Elsevier) Label-free digital pathology using infrared (IR) imaging with subsequent proteomic analysis for bladder cancer (BC) has revealed the first protein biomarker (AHNAK2) for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose. A report in The American Journal of Pathology describes this new diagnostic procedure, which is label-free, automated, observer-independent, and as sensitive and specific as established histopathological methods. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2019 Category: Cancer & Oncology Source Type: news
Go Low With Tamoxifen for DCIS Go Low With Tamoxifen for DCIS
In a potentially practice-changing result, use of a 5-mg daily dose of tamoxifen for patients with ductal carcinoma in situ (DCIS) prevented new and recurrent breast cancer events in comparison with placebo.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Radiation therapy cuts low risk of recurrence by nearly 3/4 for patients with 'good risk'
(American Society for Radiation Oncology) A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report. These 12-year follow-up data from the only prospective, randomized trial to compare recurrence outcomes after treatment for low-risk ductal carcinoma in situ (DCIS) were presented last week at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 29, 2018 Category: Cancer & Oncology Source Type: news
Radiation Therapy Cuts Recurrence in'Good Risk' DCIS Radiation Therapy Cuts Recurrence in'Good Risk' DCIS
Whole-breast radiation halved the risk for recurrence in low-risk ductal carcinoma in situ (DCIS), but treatment after surgery needs to part of a physician-patient discussion.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Lumpectomy & #43; Radiation May Cut Breast Cancer Mortality in DCIS
MONDAY, Aug. 20, 2018 -- Treatment with lumpectomy and radiotherapy is associated with a reduction in breast cancer mortality versus lumpectomy or mastectomy alone among patients with ductal carcinoma in situ (DCIS), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 20, 2018 Category: Pharmaceuticals Source Type: news
Lumpectomy Plus RT Tied to Lower Mortality in DCIS Lumpectomy Plus RT Tied to Lower Mortality in DCIS
Lumpectomy plus radiation is associated with a small but statistically significant reduced risk for breast cancer-related death compared to the other major options for ductal carcinoma in situ (DCIS).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
